WO2007014927A3 - Macrocyclic inhibitors of hepatitis c virus - Google Patents

Macrocyclic inhibitors of hepatitis c virus Download PDF

Info

Publication number
WO2007014927A3
WO2007014927A3 PCT/EP2006/064822 EP2006064822W WO2007014927A3 WO 2007014927 A3 WO2007014927 A3 WO 2007014927A3 EP 2006064822 W EP2006064822 W EP 2006064822W WO 2007014927 A3 WO2007014927 A3 WO 2007014927A3
Authority
WO
WIPO (PCT)
Prior art keywords
c6alkyl
hydrogen
crz
c6alkoxy
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/064822
Other languages
French (fr)
Other versions
WO2007014927A2 (en
Inventor
Pierre Jean-Marie Be Raboisson
Kock Herman Augustinus De
Lili Hu
Kenneth Alan Simmen
Karin Charlotta Lindquist
Mats Stefan Lindstroem
Anna Karin Gertrud Li Belfrage
Horst Juergen Waehling
Karl Magnus Nilsson
Bengt Bertil Samuelsson
Aasa Annica Kristin Rosenquist
Sven Crister Sahlberg
Hans Kristian Wallberg
Pia Cecilia Kahnberg
Bjoern Olof Classon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen R&D Ireland ULC
Medivir AB
Original Assignee
Tibotec Pharmaceuticals Ltd
Medivir AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37708968&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007014927(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US11/995,900 priority Critical patent/US7659245B2/en
Priority to KR1020087004894A priority patent/KR101083631B1/en
Priority to CN2006800278839A priority patent/CN101233131B/en
Priority to RSP-2010/0183A priority patent/RS51227B/en
Priority to HR20100209T priority patent/HRP20100209T1/en
Priority to JP2008523383A priority patent/JP5230418B2/en
Priority to NZ564540A priority patent/NZ564540A/en
Priority to HK08106903.5A priority patent/HK1116488B/en
Priority to DK06764268.6T priority patent/DK1912981T3/en
Priority to EA200800482A priority patent/EA014188B1/en
Priority to PL06764268T priority patent/PL1912981T3/en
Application filed by Tibotec Pharmaceuticals Ltd, Medivir AB filed Critical Tibotec Pharmaceuticals Ltd
Priority to EP06764268A priority patent/EP1912981B1/en
Priority to AT06764268T priority patent/ATE455775T1/en
Priority to MEP-2012-119A priority patent/ME01454B/en
Priority to CA2617103A priority patent/CA2617103C/en
Priority to AU2006274866A priority patent/AU2006274866B2/en
Priority to BRPI0614153-6A priority patent/BRPI0614153A2/en
Priority to DE602006011905T priority patent/DE602006011905D1/en
Publication of WO2007014927A2 publication Critical patent/WO2007014927A2/en
Publication of WO2007014927A3 publication Critical patent/WO2007014927A3/en
Priority to IL188320A priority patent/IL188320A/en
Anticipated expiration legal-status Critical
Priority to NO20081075A priority patent/NO20081075L/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds of the formula (I), and N-oxides, salts, and stereoisomers thereof wherein A is OR1, NHS(=O)PR2; wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl; R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl; p is independently 1 or 2; n is 3, 4, 5 or 6; ---- deonotes an optional double bond; L is N or CRz; Rz is H or forms a double bond with the asterisked carbon; Rq is H or when L is CRz, Rq can also be C1-C6alkyl; Rr is quinazolinyl, optionally substituted with one two or three substituents each independently selected from C1-C6 alkyl, C1-C6alkoxy, hydroxyl, halo, haloC1-C6alkyl, amino, mono- or dialkylamino, mono- or dialkylaminocarbonyl, C1-C6alkyl- carbonylamino, C0-C3alkylenecarbocyclyl and C0-C3 alkyleneheterocyclyl; R5 is hydrogen, C1-C6alkyl, C1-C6alkoxyC1-C6alkyl or C3-C7cycloalkyl; R6 is hydrogen, C1-C6alkyl, C1-C6alkoxy, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl, hydroxy, bromo, chloro or fluoro have utility in the treatment or prophylaxis of flaviviral infections such as HCV.
PCT/EP2006/064822 2005-07-29 2006-07-28 Macrocyclic inhibitors of hepatitis c virus Ceased WO2007014927A2 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
DE602006011905T DE602006011905D1 (en) 2005-07-29 2006-07-28 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS
EP06764268A EP1912981B1 (en) 2005-07-29 2006-07-28 Macrocyclic inhibitors of hepatitis c virus
CN2006800278839A CN101233131B (en) 2005-07-29 2006-07-28 Macrocyclic inhibitors of hepatitis c virus
RSP-2010/0183A RS51227B (en) 2005-07-29 2006-07-28 MACROCYCLIC INHIBITORS OF HEPATITIS VI
HR20100209T HRP20100209T1 (en) 2005-07-29 2006-07-28 Macrocyclic inhibitors of hepatitis c virus
JP2008523383A JP5230418B2 (en) 2005-07-29 2006-07-28 Macrocyclic inhibitor of hepatitis C virus
NZ564540A NZ564540A (en) 2005-07-29 2006-07-28 Macrocyclic inhibitors of hepatitis C virus
HK08106903.5A HK1116488B (en) 2005-07-29 2006-07-28 Macrocyclic inhibitors of hepatitis c virus
DK06764268.6T DK1912981T3 (en) 2005-07-29 2006-07-28 Macrocyclic Inhibitors of Hepatitis C Virus
KR1020087004894A KR101083631B1 (en) 2005-07-29 2006-07-28 Macrocyclic Inhibitors of Hepatitis C Virus
PL06764268T PL1912981T3 (en) 2005-07-29 2006-07-28 Macrocyclic inhibitors of hepatitis c virus
US11/995,900 US7659245B2 (en) 2005-07-29 2006-07-28 Macrocylic inhibitors of hepatitis C virus
MEP-2012-119A ME01454B (en) 2005-07-29 2006-07-28 Macrocyclic inhibitors of hepatitis e virus
EA200800482A EA014188B1 (en) 2005-07-29 2006-07-28 Macrocyclic inhibitors of hepatitis c virus
AT06764268T ATE455775T1 (en) 2005-07-29 2006-07-28 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS
CA2617103A CA2617103C (en) 2005-07-29 2006-07-28 Macrocyclic inhibitors of hepatitis c virus
AU2006274866A AU2006274866B2 (en) 2005-07-29 2006-07-28 Macrocyclic inhibitors of hepatitis C virus
BRPI0614153-6A BRPI0614153A2 (en) 2005-07-29 2006-07-28 macrocyclic hepatitis c virus inhibitors and pharmaceutical composition containing them
IL188320A IL188320A (en) 2005-07-29 2007-12-20 Macrocyclic inhibitors of hepatitis c virus, pharmaceutical compositions comprising them and their manufacture
NO20081075A NO20081075L (en) 2005-07-29 2008-02-29 Macrocyclic inhibitors of hepatitis C virus

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05107057.1 2005-07-29
EP05107057 2005-07-29
EP06113097 2006-04-25
EP06113097.7 2006-04-25

Publications (2)

Publication Number Publication Date
WO2007014927A2 WO2007014927A2 (en) 2007-02-08
WO2007014927A3 true WO2007014927A3 (en) 2007-11-29

Family

ID=37708968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/064822 Ceased WO2007014927A2 (en) 2005-07-29 2006-07-28 Macrocyclic inhibitors of hepatitis c virus

Country Status (31)

Country Link
US (1) US7659245B2 (en)
EP (1) EP1912981B1 (en)
JP (1) JP5230418B2 (en)
KR (1) KR101083631B1 (en)
AP (1) AP2585A (en)
AR (1) AR057702A1 (en)
AT (1) ATE455775T1 (en)
AU (1) AU2006274866B2 (en)
BR (1) BRPI0614153A2 (en)
CA (1) CA2617103C (en)
CY (1) CY1110008T1 (en)
DE (1) DE602006011905D1 (en)
DK (1) DK1912981T3 (en)
EA (1) EA014188B1 (en)
ES (1) ES2339702T3 (en)
GT (1) GT200600343A (en)
HR (1) HRP20100209T1 (en)
IL (1) IL188320A (en)
ME (1) ME01454B (en)
MY (1) MY151026A (en)
NO (1) NO20081075L (en)
NZ (1) NZ564540A (en)
PE (1) PE20070343A1 (en)
PL (1) PL1912981T3 (en)
PT (1) PT1912981E (en)
RS (1) RS51227B (en)
SI (1) SI1912981T1 (en)
SV (1) SV2008002641A (en)
TW (1) TWI387597B (en)
UY (1) UY29704A1 (en)
WO (1) WO2007014927A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8614180B2 (en) 2008-12-10 2013-12-24 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8785378B2 (en) 2006-07-13 2014-07-22 Achillion Pharmaceuticals, Inc. Macrocyclic peptides as inhibitors of viral replication
US8993595B2 (en) 2009-04-08 2015-03-31 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
US9227940B2 (en) 2002-05-20 2016-01-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2336009T3 (en) 2004-01-30 2010-04-07 Medivir Ab INHIBITORS OF THE NS-3 SERINA PROTEASA HCV.
PE20070211A1 (en) * 2005-07-29 2007-05-12 Medivir Ab MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS
BRPI0614637A2 (en) 2005-07-29 2011-04-12 Tibotec Pharm Ltd macrocyclic hepatitis c virus inhibitors
JO2768B1 (en) * 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Macrocylic Inhibitors Hepatitis C Virus
RU2436787C2 (en) 2005-07-29 2011-12-20 Тиботек Фармасьютикалз Лтд. Macrocyclic hepatitis c inhibitors
EA200801050A1 (en) 2005-10-11 2008-12-30 Интермьюн, Инк. COMPOUNDS AND METHODS OF INHIBITING THE REPLICATION OF VIRAL HEPATITIS C
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2008152171A (en) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) NEW HEPATITIS C VIRAL REPLICATION INHIBITORS
WO2008008776A2 (en) 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008059046A1 (en) * 2006-11-17 2008-05-22 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
RU2483067C2 (en) * 2007-02-01 2013-05-27 Тиботек Фармасьютикалз Лтд. Methods and intermediate products for producing macrocyclic hepatitis c virus protease inhibitor
RU2481340C2 (en) * 2007-02-08 2013-05-10 Тиботек Фармасьютикалз Лтд. Pyrimidine substituted macrocyclic hcv inhibitors
ITMI20071616A1 (en) 2007-08-03 2009-02-04 Cosmo Spa ENZYMATIC PROCESS FOR THE OBTAINING OF 17-ALFA MONOESTERS OF CORTEXOLONE AND / OR ITS 9,11-DEIDRODERIVATI.
CA2700383A1 (en) * 2007-09-24 2009-04-02 Achillion Pharmaceuticals, Inc. Urea-containing peptides as inhibitors of viral replication
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8426360B2 (en) * 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
US8263549B2 (en) 2007-11-29 2012-09-11 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
WO2009084695A1 (en) 2007-12-28 2009-07-09 Carna Biosciences Inc. 2-aminoquinazoline derivative
CA2719008A1 (en) 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis c virus inhibitors
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102046648A (en) 2008-05-29 2011-05-04 百时美施贵宝公司 Hepatitis c virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (en) * 2008-09-11 2010-04-30 Enanta Pharm Inc HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SMT201700121T1 (en) 2009-02-27 2017-03-08 Janssen Pharmaceuticals Inc Amorphous salt of a macrocyclic inhibitor of hcv
US20120129875A1 (en) * 2009-05-29 2012-05-24 Syngenta Crop Protection, Llc Substituted quinazolines as fungicides
KR20140003521A (en) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 Phenanthridine macrocyclic hepatitis c serine protease inhibitors
CN103534256B (en) 2010-12-30 2016-08-10 益安药业 Macrocyclic hepatitis c serine protease inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX340033B (en) 2011-12-28 2016-06-21 Janssen Sciences Ireland Uc Hetero-bicyclic derivatives as hcv inhibitors.
MX348338B (en) * 2012-10-15 2017-06-07 Albemarle Corp Processes for the synthesis of 2-amino-4,6-dimethoxybenzamide and other benzamide compounds.
JP6154474B2 (en) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Hepatitis C virus inhibitor
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP3108879A1 (en) 2015-06-25 2016-12-28 Cassiopea S.p.A. High concentration formulation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053349A2 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Inhibitors of hepatitis c virus
WO2004037855A1 (en) * 2002-10-25 2004-05-06 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
WO2005028501A1 (en) * 2003-09-22 2005-03-31 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
EP1497282A2 (en) 2002-04-11 2005-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4 protease
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20040180815A1 (en) * 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
CN1771050A (en) * 2003-02-07 2006-05-10 益安药业 Macrocyclic inhibitors of hepatitis C serine protease
ATE422895T1 (en) * 2003-04-16 2009-03-15 Bristol Myers Squibb Co MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
ES2336009T3 (en) * 2004-01-30 2010-04-07 Medivir Ab INHIBITORS OF THE NS-3 SERINA PROTEASA HCV.
EP1910347A2 (en) * 2005-07-29 2008-04-16 Medivir Ab Macrocylic inhibitors of hepatitis c virus
PE20070211A1 (en) * 2005-07-29 2007-05-12 Medivir Ab MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS
EP1919904B1 (en) * 2005-07-29 2014-01-08 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis c virus
AR055105A1 (en) * 2005-07-29 2007-08-08 Tibotec Pharm Ltd MACROCICLIC INHIBITORS OF HEPATITIS C VIRUS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053349A2 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Inhibitors of hepatitis c virus
WO2004037855A1 (en) * 2002-10-25 2004-05-06 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
WO2005028501A1 (en) * 2003-09-22 2005-03-31 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227940B2 (en) 2002-05-20 2016-01-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8785378B2 (en) 2006-07-13 2014-07-22 Achillion Pharmaceuticals, Inc. Macrocyclic peptides as inhibitors of viral replication
US9233136B2 (en) 2006-07-13 2016-01-12 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8614180B2 (en) 2008-12-10 2013-12-24 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US9133115B2 (en) 2008-12-10 2015-09-15 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8993595B2 (en) 2009-04-08 2015-03-31 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof

Also Published As

Publication number Publication date
PE20070343A1 (en) 2007-05-12
PT1912981E (en) 2010-04-16
ES2339702T3 (en) 2010-05-24
KR20080033475A (en) 2008-04-16
PL1912981T3 (en) 2010-07-30
ATE455775T1 (en) 2010-02-15
US20090118312A1 (en) 2009-05-07
GT200600343A (en) 2007-08-06
SV2008002641A (en) 2008-07-23
RS51227B (en) 2010-12-31
JP2009502890A (en) 2009-01-29
HK1116488A1 (en) 2008-12-24
US7659245B2 (en) 2010-02-09
DE602006011905D1 (en) 2010-03-11
AU2006274866A1 (en) 2007-02-08
EP1912981B1 (en) 2010-01-20
EA200800482A1 (en) 2008-06-30
AU2006274866B2 (en) 2012-04-12
IL188320A (en) 2014-07-31
WO2007014927A2 (en) 2007-02-08
HRP20100209T1 (en) 2010-05-31
CA2617103C (en) 2015-01-06
CA2617103A1 (en) 2007-02-08
NO20081075L (en) 2008-04-25
JP5230418B2 (en) 2013-07-10
TW200745116A (en) 2007-12-16
SI1912981T1 (en) 2010-05-31
EA014188B1 (en) 2010-10-29
TWI387597B (en) 2013-03-01
DK1912981T3 (en) 2010-05-25
IL188320A0 (en) 2008-04-13
AR057702A1 (en) 2007-12-12
CY1110008T1 (en) 2015-01-14
MY151026A (en) 2014-03-31
EP1912981A2 (en) 2008-04-23
UY29704A1 (en) 2007-05-31
AP2585A (en) 2013-02-04
KR101083631B1 (en) 2011-11-16
NZ564540A (en) 2010-03-26
ME01454B (en) 2014-04-20
BRPI0614153A2 (en) 2011-03-15

Similar Documents

Publication Publication Date Title
TW200745116A (en) Macrocylic inhibitors of hepatitis C virus
WO2007017144A3 (en) Macrocylic inhibitors of hepatitis c virus
TW200833332A (en) New amino nicotinic and isonicotinic acid derivatives
GEP20084500B (en) Heterocyclocarboxamide derivatives
MXPA05009771A (en) Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient.
MY154772A (en) Harmful arthropod control composition, and fused heterocyclic compound
EP1736471A4 (en) 3- (DIHYDRO (tetrahydro) isoquinolin-1-YL) QUINOLINES
PL367348A1 (en) 2-amino-propanol derivatives
PH12012501711A1 (en) [5,6] heterocyclic compound
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
MX2008001394A (en) Macrocyclic inhibitors of hepatitis c virus.
WO2008081852A1 (en) Composition and light-emitting element comprising the composition
DE60309836D1 (en) CRYSTALS ZEOLITHIC ALUMINOSILICATE COMPOSITION: UZM-9
WO2008126890A1 (en) Hydrazide compound and harmful arthropod-controlling agent containing the same
MX2009013833A (en) Crystalline pyridazine compound.
WO2003035620A1 (en) Bicyclic compound
NO20076680L (en) Selected CGRP antagonists, methods for their preparation and their use as drugs
TW200742758A (en) Photosensitizer dye
TW200635901A (en) Amide derivatives
PL372409A1 (en) Novel alkoxypyridine-derivatives
NO20053570L (en) Thermostable, water-soluble polymer that is crosslinkable at high temperatures
WO2008042497A3 (en) Benzoxazole and benzothiazole compounds useful as authentication compounds in polymer articles
TW200732338A (en) Aromatic compound
UA93377C2 (en) Macrocyclic inhibitors of hepatitis c virus
GB0324210D0 (en) Organic compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006764268

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 564540

Country of ref document: NZ

Ref document number: 1200702725

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 188320

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006274866

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: AP/P/2008/004306

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: 11995900

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 631/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008010149

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/001393

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008523383

Country of ref document: JP

Ref document number: 2617103

Country of ref document: CA

Ref document number: 200680027883.9

Country of ref document: CN

Ref document number: 12008500256

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006274866

Country of ref document: AU

Date of ref document: 20060728

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006274866

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020087004894

Country of ref document: KR

Ref document number: 200800482

Country of ref document: EA

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06764268

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2006764268

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: P-2010/0183

Country of ref document: RS

ENP Entry into the national phase

Ref document number: PI0614153

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080129